Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - spironolactone 25 mg - film-coated tablet - spironolactone

United States - English - NLM (National Library of Medicine)

greenstone llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: essential hypertension: control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - spironolactone - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - spironolactone - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - spironolactone - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - spironolactone - oral tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - spironolactone - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

northstar healthcare unlimited company - spironolactone - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - spironolactone - oral tablet - 100mg

United States - English - NLM (National Library of Medicine)

prasco laboratories - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: congestive heart failure: cirrhosis of the liver accompanied by edema and/or ascites: the nephrotic syndrome: essential hypertension: control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr